• Latest Posts

BioGeneration Ventures closes BGV Fund V at €150M 

Expert Advice 2 Mar 2023

5 steps to strategic partnerships for healthtech startups

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF


Treatment for adults with moderate to severe psoriasis approved by FDA

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

In Depth 9 Apr 2018

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial